CD8A and neoplasm: ICI therapy may also be used in combination with anti-angiogenic inhibitors (such as anti-VEGF antibodies) [127], poly (ADP ribose) polymerase (PARP) inhibitors [128], or epigenetic modifiers (such as decitabine) [129,130], all of which can result in heightened CD8+ T cell anti-tumor responses through a variety of mechanisms.